Segall Bryant & Hamill LLC decreased its stake in Stryker Corporation (NYSE:SYK) by 1.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 31,214 shares of the medical technology company’s stock after selling 505 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in Stryker were worth $4,433,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Coldstream Capital Management Inc. grew its position in shares of Stryker by 3.7% in the second quarter. Coldstream Capital Management Inc. now owns 17,445 shares of the medical technology company’s stock valued at $2,421,000 after purchasing an additional 626 shares during the period. Retirement Systems of Alabama grew its position in shares of Stryker by 2.5% in the third quarter. Retirement Systems of Alabama now owns 234,870 shares of the medical technology company’s stock valued at $33,356,000 after purchasing an additional 5,656 shares during the period. Lockheed Martin Investment Management Co. acquired a new stake in shares of Stryker in the second quarter valued at about $1,249,000. Toronto Dominion Bank grew its position in shares of Stryker by 25.8% in the second quarter. Toronto Dominion Bank now owns 105,403 shares of the medical technology company’s stock valued at $14,625,000 after purchasing an additional 21,585 shares during the period. Finally, Colonial Trust Advisors grew its position in shares of Stryker by 56.1% in the second quarter. Colonial Trust Advisors now owns 23,446 shares of the medical technology company’s stock valued at $3,254,000 after purchasing an additional 8,426 shares during the period. Institutional investors and hedge funds own 74.97% of the company’s stock.

Several analysts have recently issued reports on the stock. SunTrust Banks reiterated a “buy” rating and issued a $161.00 target price on shares of Stryker in a research report on Monday, October 2nd. Oppenheimer set a $156.00 target price on shares of Stryker and gave the company a “hold” rating in a research report on Monday, October 30th. Canaccord Genuity lifted their target price on shares of Stryker from $155.00 to $162.00 and gave the company a “buy” rating in a research report on Friday, October 27th. Zacks Investment Research lowered shares of Stryker from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. Finally, Cowen set a $160.00 price target on shares of Stryker and gave the stock a “buy” rating in a research report on Friday, October 6th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and thirteen have given a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $152.10.

In other Stryker news, insider Lonny J. Carpenter sold 5,000 shares of Stryker stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $155.34, for a total transaction of $776,700.00. Following the transaction, the insider now directly owns 83,207 shares of the company’s stock, valued at $12,925,375.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 7.40% of the stock is owned by insiders.

Shares of Stryker Corporation (NYSE:SYK) traded up $0.78 during mid-day trading on Friday, reaching $151.93. 688,011 shares of the company’s stock were exchanged, compared to its average volume of 1,098,233. The company has a quick ratio of 1.61, a current ratio of 2.37 and a debt-to-equity ratio of 0.63. Stryker Corporation has a one year low of $115.75 and a one year high of $160.62. The stock has a market capitalization of $56,857.98, a P/E ratio of 24.08, a PEG ratio of 2.39 and a beta of 0.78.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, October 26th. The medical technology company reported $1.52 EPS for the quarter, topping analysts’ consensus estimates of $1.50 by $0.02. Stryker had a net margin of 14.67% and a return on equity of 24.11%. The company had revenue of $3.01 billion for the quarter, compared to the consensus estimate of $2.97 billion. During the same period in the previous year, the firm earned $1.39 earnings per share. Stryker’s quarterly revenue was up 6.1% compared to the same quarter last year. analysts anticipate that Stryker Corporation will post 6.47 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 31st. Shareholders of record on Friday, December 29th will be paid a dividend of $0.47 per share. The ex-dividend date of this dividend is Thursday, December 28th. This is an increase from Stryker’s previous quarterly dividend of $0.43. This represents a $1.88 dividend on an annualized basis and a yield of 1.24%. Stryker’s payout ratio is 36.32%.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/12/10/stryker-corporation-syk-shares-sold-by-segall-bryant-hamill-llc.html.

Stryker Company Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.